Neuroendocrine Cancer Will Face Tough Fight Against Strong Future Treatment Options
London, England -- (SBWIRE) -- 06/08/2012 -- Exciting clinical developments in the field of neuroendocrine carcinoma mean that patients are likely to receive a host of new treatment options within the next few years, according to a new report by healthcare intelligence company GlobalData.
The new report shows several new drugs are anticipated to be launched in the coming years, along with a multitude of upcoming pipeline drugs, which are expected to revolutionize the currently accepted treatment for the cancer.
The pancreatic neuroendocrine tumors (NET) therapeutics market is currently dominated by two recently approved drugs, Sutent (sunitinib) and Afinitor (everolimus). While these drugs each display high efficacy and are expected to delay disease progression, both are associated with serious side effects. Therefore, safer medications are desperately sought by patients and physicians. GI carcinoid NET patients also have need for more treatment choices, as Sandostatin LAR (octreotide) is the only currently approved drug and individuals are at risk of developing resistance against certain Somatostatin (SST) analogs such as octreotide and lanreotide.
High market growth is anticipated in the future, primarily due to new medications due for launch, including Avastin (bevacizumab) and Lutathera ([177Lutetium]-DOTA0- Tyr3-Octreotate) for gastrointestinal (GI) carcinoid and pancreatic NETs, and pasireotide (SOM 230) and Somatuline (lanreotide acetate) Autogel/Depot for GI carcinoids NETs. GlobalData research indicates that the neuroendocrine carcinoma pipeline is also strong, with 15 molecules in different phases of development. These drugs are expected to change the treatment paradigm, offering lower side effects and bringing with them a strong level of market competition between pharmaceutical companies.
For Sample Pages, please click or add the below link to your browser:
GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019.
This report is an essential source of information and analysis on the global neuroendocrine carcinoma market, which identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData is a leading global business intelligence provider offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.globaldata.com/reportstore
For more details contact:
+1 646 395 5477
+44 207 753 4299
+44 1204 543 533
+91 40 6616 6782
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)